Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group

• Authors: Deborah F. Billmire, Riley Hospital for Children; John W. Cullen, Rocky Mountain Hospital for Children; Frederick J. Rescorla, Riley Hospital for Children; Mary Davis, Helen DeVos Children's Hospital at Spectrum Health; Marc G. Schlatter, Helen DeVos Children's Hospital at Spectrum Health; Thomas Olson, Emory University; Marcio H. Malogolowkin, Medical College of Wisconsin; Farzana Pashankar, Yale University; Doojduen Villaluna, Children's Oncology Group; Mark Krailo, University of Southern California; Rachel A. Egler, Rainbow Babies and Children's Hospital; Carlos Rodriguez-Galindo, Dana-Farber Cancer Institute; A. Lindsay Frazier, Dana-Farber Cancer Institute
• Journal Title: Journal of Clinical Oncology
• Volume: Volume 32, Number 5
• Publisher: American Society of Clinical Oncology | 2014-02-10, Pages 465-470
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1200/JCO.2013.51.1006
• Subjects: Health Sciences, Oncology; Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Oncology; TESTICULAR CANCER; INTERGROUP; CHEMOTHERAPY; BLEOMYCIN; ETOPOSIDE; POLICY

Abstract

Purpose To determine whether overall survival (OS) can be preserved for patients with stage I pediatric malignant ovarian germ cell tumor (MOGCT) with an initial strategy of surveillance after surgical resection. Patients and Methods Between November 2003 and July 2011, girls age 0 to 16 years with stage I MOGCT were enrolled onto Children's Oncology Group study AGCT0132. Required histology included yolk sac, embryonal carcinoma, or choriocarcinoma. Surveillance included measurement of serum tumor markers and radiologic imaging at defined intervals. In those with residual or recurrent disease, chemotherapy with compressed PEB (cisplatin, etoposide, and bleomycin) was initiated every 3 weeks for three cycles (cisplatin 33 mg/m2 on days 1 to 3, etoposide 167 mg/m2 on days 1 to 3, bleomycin 15 U/m2 on day 1). Survivor functions for event-free survival (EFS) and OS were estimated using the Kaplan-Meier method. Results Twenty-five girls (median age, 12 years) with stage I MOGCT were enrolled onto AGCT0132. Twenty-three patients had elevated alpha-fetoprotein (AFP) at diagnosis. Predominant histology was yolk sac. After a median follow-up of 42 months, 12 patients had evidence of persistent or recurrent disease (4-year EFS, 52%; 95% CI, 31% to 69%). Median time to recurrence was 2 months. All patients had elevated AFP at recurrence; six had localized disease, two had metastatic disease, and four had tumor marker elevation only. Eleven of 12 patients experiencing relapse received successful salvage chemotherapy (4-year OS, 96%; 95% CI, 74% to 99%). Conclusion Fifty percent of patients with stage I pediatric MOGCT can be spared chemotherapy; treatment for those who experience recurrence preserves OS. Further study is needed to identify the factors that predict recurrence and whether this strategy can be extended successfully to older adolescents and young adults.